Vanda Pharmaceuticals is riding a regulatory roller coaster over the last few months. | Vanda Pharmaceuticals is riding a ...

Vanda Pharmaceuticals’ seven-year ambition to score a coveted label expansion for sleep drug Hetlioz has taken an unusual turn, with the FDA acquiescing to a formal hearing on the matter. | The ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a formal evidentiary public hearing to review ...

Analysts have set 12-month price targets for Vanda Pharmaceuticals, revealing an average target of $16.88, a high estimate of $24.00, and a low estimate of $7.50. Marking an increase of 16.41%, the ...

B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $17 from $14 and keeps a Buy rating on the shares. Following BYSANTI’s approval, the firm’s revenue model for Vanda has been ...

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) surged about 33% to $7.68 in premarket trading Monday after the company ...

A D.C. drugmaker just scored a rate public hearing with the FDA around a jet lag drug. It marks the first time the agency has agreed to hold such a meeting in decades.

Shares of Vanda Pharmaceuticals Inc. VNDA rose sharply in pre-market trading after the company reported the FDA approval of ...

Bysanti is based on iloperidone, an active metabolite of a compound that forms the core of Fanapt, another drug by Vanda Pharmaceuticals.

Vanda Pharmaceuticals VNDA stock: surges 44% after FDA approves BYSANTI for Bipolar I and Schizophrenia, with patent protection until 2044 and a Q3 2026 launch.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate ...